Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,173 questions in 89 reviews · Neuromuscular
current versionsNo studies 302 · 25.7%Ungraded 119 · 10.1%Very low 267 · 22.8%Low 239 · 20.4%Moderate 177 · 15.1%High 69 · 5.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Interferon beta‐1a vs placebo Change in muscle mass at 6 months (%) · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | 2 studies · 58 participants | Moderate |
Mycophenolate mofetil vs placebo Improvement in GNDS after 12 months1 · people with multifocal motor neuropathy Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy (2015) · Cochrane | RR 0.54 [0.06, 5.26] | 1 study · 28 participants | Moderate |
Mycophenolate mofetil vs placebo Serious adverse events · people with multifocal motor neuropathy Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy (2015) · Cochrane | no estimate extracted | 1 study · 28 participants | Moderate |
Plasma exchange vs sham exchange Change in disability after 4 weeks disability grade change. Scale from: 0 to 10; lower is better · people with CIDP Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy (2015) · Cochrane | no estimate extracted | 1 study · 36 participants | Moderate |
Plasma exchange vs sham exchange Change in impairment (NIS) after 4 weeks NIS score points. Scale from: 0 to 280; lower is better · people with CIDP Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy (2015) · Cochrane | no estimate extracted | 2 studies · 59 participants | High |
Plasma exchange vs sham exchange Change in mean compound muscle action potential amplitude after 4 weeks mA · people with CIDP Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy (2015) · Cochrane | no estimate extracted | 1 study · 30 participants | Moderate |
Plasma exchange vs sham exchange Serious adverse events ‐ not measured · people with CIDP Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy (2015) · Cochrane | no estimate extracted | NR | No studies |
Plasma exchange vs sham exchange Only 1 trial. · people with CIDP Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy (2015) · Cochrane | no estimate extracted | 1 study · 1 participants | Ungraded |
Quinine vs placebo Number of cramps over 2 weeks · people with muscle cramps Quinine for muscle cramps (2015) · Cochrane | no estimate extracted | 13 studies · 952 participants | Low |
Quinine vs a quinine‐vitamin E combination (Q‐Vel) Cramp intensity (on 3‐point scale; 1 = mild; 2 = moderate; 3 = severe) · people with muscle cramps Quinine for muscle cramps (2015) · Cochrane | no estimate extracted | 3 studies · 510 participants | Low |
Quinine vs a quinine‐vitamin E combination (Q‐Vel) Participants suffering major adverse events · people with muscle cramps Quinine for muscle cramps (2015) · Cochrane | no estimate extracted | 3 studies · 510 participants | Moderate |
Quinine vs a quinine‐vitamin E combination (Q‐Vel) Participants suffering minor adverse events · people with muscle cramps Quinine for muscle cramps (2015) · Cochrane | no estimate extracted | 3 studies · 510 participants | Moderate |
Quinine vs placebo Cramp intensity (on 3‐point scale; 1 = mild; 2 = moderate; 3 = severe) · people with muscle cramps Quinine for muscle cramps (2015) · Cochrane | no estimate extracted | 7 studies · 666 participants | Moderate |
Quinine vs placebo Participants suffering major adverse events · people with muscle cramps Quinine for muscle cramps (2015) · Cochrane | no estimate extracted | 18 studies · 1103 participants | Moderate |
Quinine vs placebo Participants suffering minor adverse events · people with muscle cramps Quinine for muscle cramps (2015) · Cochrane | no estimate extracted | 16 studies · 969 participants | Moderate |
Quinine vs vitamin E Number of cramps over 2 weeks · people with muscle cramps Quinine for muscle cramps (2015) · Cochrane | no estimate extracted | 3 studies · 513 participants | Low |
Quinine vs vitamin E Cramp intensity (on 3‐point scale; 1 = mild; 2 = moderate; 3 = severe) · people with muscle cramps Quinine for muscle cramps (2015) · Cochrane | no estimate extracted | 3 studies · 513 participants | Moderate |
Quinine vs vitamin E Participants suffering major adverse events · people with muscle cramps Quinine for muscle cramps (2015) · Cochrane | no estimate extracted | 3 studies · 513 participants | Moderate |
Quinine vs vitamin E Participants suffering minor adverse events · people with muscle cramps Quinine for muscle cramps (2015) · Cochrane | no estimate extracted | 2 studies · 483 participants | Moderate |
Quinine vs a quinine‐vitamin E combination (Q‐Vel) Number of cramps over 2 weeks · people with muscle cramps Quinine for muscle cramps (2015) · Cochrane | no estimate extracted | 2 studies · 486 participants | Low |
Plasma exchange (PE) vs sham exchange Change in disability Neuropathy Disability Score · people with IgG and IgA paraproteinaemic neuropathy Treatment for IgG and IgA paraproteinaemic neuropathy (2015) · Cochrane | no estimate extracted | 1 study · 18 participants | Low |
Plasma exchange (PE) vs sham exchange Change in sensation using a validated scale (e.g. INCAT sensory sum score) ‐ not measured · people with IgG and IgA paraproteinaemic neuropathy Treatment for IgG and IgA paraproteinaemic neuropathy (2015) · Cochrane | no estimate extracted | NR | No studies |
Plasma exchange (PE) vs sham exchange Change in strength Neuropathy Disability Score (weakness) · people with IgG and IgA paraproteinaemic neuropathy Treatment for IgG and IgA paraproteinaemic neuropathy (2015) · Cochrane | no estimate extracted | 1 study · 18 participants | Low |
Plasma exchange (PE) vs sham exchange Adverse events ‐ not reported · people with IgG and IgA paraproteinaemic neuropathy Treatment for IgG and IgA paraproteinaemic neuropathy (2015) · Cochrane | no estimate extracted | NR | No studies |
IVIg vs placebo (Change in) Activity limitations ≤ 3 months · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 2 studies · 185 participants | Moderate |
Amantadine vs placebo Activity limitations ‐ not measured · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Amantadine vs placebo Adverse events · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 1 study · 25 participants | Ungraded |
Prednisone vs placebo Activity limitations ‐ not measured · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Prednisone vs placebo Adverse events · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 1 study · 17 participants | Ungraded |
Muscle strengthening vs control Activity limitations ‐ not measured · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Muscle strengthening vs control Adverse events · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 1 study · 10 participants | Ungraded |
Rehabilitation in cold climate vs usual care Activity limitations at 3 months · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 1 study · 53 participants | Low |
Rehabilitation in cold climate vs usual care Activity limitations at 6 months · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 1 study · 53 participants | Low |
Rehabilitation in cold climate vs usual care Activity limitations at 3 months · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 1 study · 53 participants | Low |
Rehabilitation in cold climate vs usual care Activity limitations at 6 months · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 1 study · 53 participants | Low |
IVIg vs placebo Activity limitations > 3 months · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 2 studies · 91 participants | Low |
Rehabilitation in cold climate vs usual care Adverse events ‐ not measured · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation in warm climate vs usual care Activity limitations 3 months · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 1 study · 57 participants | Low |
Rehabilitation in warm climate vs usual care Activity limitations 3 months · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 1 study · 57 participants | Low |
Rehabilitation in warm climate vs usual care Adverse events ‐ not measured · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Static magnetic fields vs placebo Activity limitations ‐ not measured · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Static magnetic fields vs placebo Adverse events · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 1 study · 50 participants | Ungraded |
IVIg vs placebo Adverse events · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 3 studies · 212 participants | Ungraded |
Modafinil vs placebo Activity limitations · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 1 study · 33 participants | High |
Modafinil vs placebo Adverse events · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 2 studies · 50 participants | Ungraded |
Pyridostigmine vs placebo Change in activity limitations · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 1 study · 124 participants | Moderate |
Pyridostigmine vs placebo Adverse events · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 2 studies · 193 participants | Ungraded |
Lamotrigine vs control Activity limitations · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 1 study · 30 participants | Very low |
Lamotrigine vs control Adverse events · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | 1 study · 30 participants | Ungraded |
Gabapentin vs placebo Number of patients with self reported pain relief of 50% or greater (not measured) · patients with pain in Guillain‐Barré syndrome Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |